Avid Bioservices, Inc. (CDMO)
| Market Cap | 798.90M |
| Revenue (ttm) | 150.45M +6.7% |
| Net Income | -152.05M |
| EPS | -2.39 |
| Shares Out | 63.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 12.49 |
| Previous Close | 12.49 |
| Day's Range | 12.49 - 12.49 |
| 52-Week Range | 5.90 - 12.51 |
| Beta | 1.39 |
| Analysts | Hold |
| Price Target | 12.25 (-1.92%) |
| Earnings Date | Dec 10, 2024 |
About CDMO
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line developme... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CDMO stock is "Hold." The 12-month stock price target is $12.25, which is a decrease of -1.92% from the latest price.
News
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...
Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger
TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improv...
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners (“Ampers...
Avid Stockholders Approve Transaction with GHO and Ampersand
TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) wo...
Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand
Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders Mails Letter to Stockholders Highlighting the Significant, Immediat...
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
TUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) wo...
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices...
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
TUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) wo...
Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction
TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) wo...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...